-
In early November 2025, Keysight Technologies introduced new high-density automated test equipment, advanced quantum simulation tools, and MediaTek announced a partnership with Keysight to showcase breakthroughs in pre-6G integrated sensing…
Category: 6. Business
-
How Investors May Respond To Keysight Technologies (KEYS) Quantum and Pre-6G Tech Collaboration With MediaTek
-
1 Surprising Way Taiwan Semiconductor Manufacturing (TSMC) Makes Money
-
Surging demand for AI and the ongoing data center build-out have fueled robust growth for Taiwan Semiconductor Manufacturing (TSMC).
-
While high-end processors represent the majority of its sales, a legacy business has begun to…
Continue Reading
-
-
Crypto Wrap: 'OG' Whale Dumping and US Investor Flight Blamed for Crypto's $260 Billion Contraction – Bitcoin.com News
- Crypto Wrap: ‘OG’ Whale Dumping and US Investor Flight Blamed for Crypto’s $260 Billion Contraction Bitcoin.com News
- Bitcoin slumps nearly 20% from all-time high as strategist warns ‘we could correct quite a bit more’ Yahoo Finance
- Bitcoin, XRP,…
Continue Reading
-
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
– 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated glomerular filtration rate…
Continue Reading
-
Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk – The Washington Post
- Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk The Washington Post
- Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits CNBC
- Pfizer to Acquire Obesity Drug Start-Up Metsera in $10…
Continue Reading
-
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
- Deep, stable and durable reductions in kallikrein observed
- Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff:
- 31 (97%) were attack-free and long-term prophylaxis (LTP)-free
- 24 (75%)…
Continue Reading
-
Assessing Valuation After Recent Momentum in Share Performance
MSCI (MSCI) recently caught investors’ attention after its performance over the past month saw shares rise by nearly 3%. With steady annual revenue and net income growth, many are watching to see whether this momentum will continue.
See…
Continue Reading
-
More than 1,000 flights cancelled as US air traffic cuts enter second day
Getty ImagesTravellers wait in a long line at a security checkpoint at Houston’s George Bush Intercontinental Airport on 6 November More than 1,000 flights to, from, or within the US were cancelled on Saturday after airlines were told this week to…
Continue Reading
-
Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs
Pending the results of the ongoing phase 3 SORENTO trial (NCT05050942), increasing the dose or shortening the treatment interval of somatostatin analogs may be a viable route to take for patients with gastroenteropancreatic neuroendocrine tumors…
Continue Reading
-
Evaluating Valuation After Recent Share Price Pullback
ACI Worldwide (ACIW) shares moved lower after the company’s latest trading session, closing down 3% to $48.96. While the decline caught some attention, it follows an otherwise resilient performance over the past month.
See our latest…
Continue Reading
